Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Pembrolizumab
Indication/Tumor Type esophagus squamous cell carcinoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive esophagus squamous cell carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced esophageal squamous carcinoma expressing PD-L1 (CD274, CPS>=10), and as second or subsequent lines of treatment for previously treated patients who have not received immunotherapy and with CPS>=10 (PMID: 35914638; ESMO.org). detail... 35914638
CD274 positive esophagus squamous cell carcinoma sensitive Pembrolizumab FDA approved - On Companion Diagnostic Actionable In a Phase III trial (KEYNOTE-181) that supported FDA approval, Keytruda (pembrolizumab) treatment as second-line therapy improved overall survival (OS) (9.3 vs 6.7 months, HR=0.69, p=0.0074) and 12-month OS rate (43% vs 20%) compared to chemotherapy in patients with esophagus squamous cell carcinoma with a CPS of 10 or higher (PMID: 33026938; NCT02564263). detail... detail... 33026938
CD274 positive esophagus squamous cell carcinoma sensitive Pembrolizumab Guideline Actionable Keytruda (pembrolizumab) is included in guidelines as a preferred second-line or subsequent therapy (category 1) for patients with CD274 (PD-L1)-positive (CPS >/=10), unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (NCCN.org). detail...
PubMed Id Reference Title Details
NCCN.org Full reference...
ESMO Clinical Practice Guidelines Full reference...
Full reference...
Keytruda (pembrolizumab) FDA Drug Label Full reference...
(33026938) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Full reference...
(35914638) Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Full reference...